Search

Meet the Swiss Biotech Association. We spoke with Michael Altorfer, CEO, to gain insights into the Swiss biotech ecosystem as the invited country for BIOSPAIN 2025.

At AseBio, we are celebrating the third edition of the program "A Day with a Biotech Woman," which introduces female students to the inner workings of a biotechnology company and the various career

All bioprocessing requirements in one, every detail of every application meticulously addressed.

The head of the Government of Extremadura has been able to check the progress of the Sustainext project, a European initiative led by Natac that will transform this production center into the most

La revista Frontiers in Psychiatry publica un estudio que proporciona escalas clínicas y umbrales para la selección de pacientes en futuros ensayos clínicos, basados en la agresividad, la cognición y

The Balearic Biotechnology and Biomedical Cluster (BIOIB) is leading a pioneering study in Spain on the impact of public affairs on this sector’s development and its social legitimization.

CONNECTA Therapeutics has achieved positive results in the Phase I clinical trial of CTH120, an investigational drug that modulates neuroplasticity to treat neurodevelopmental disorders such as

Expertos líderes en psiquiatría en EE.UU. se unen al Comité Asesor Clínico (CAC) de Oryzon para avanzar en el desarrollo de la Fase III de vafidemstat en Trastorno Límite de la Personalidad (TLP).

Pharmaron accelerates drug discovery by transforming scientific breakthroughs into therapies, using advanced technologies and a global team of 8,500+ chemists. They specialize in small molecules

Se han realizado inversiones en I+D por importe de 8,3 M€, de las cuales 7,6 M€ corresponden a desarrollo y 0,7 M€ a investigación. Tras la finalización del ensayo clínico PORTICO, la intensidad en

CENER reaffirms its commitment to innovation and sustainability through the BIOOLE-UP research and development project, positioning itself as a benchmark in biorefinery applied to global social

Despite advances in biotechnology and research, the lack of specialists, scarcity of treatments, and inequality in access to medical services remain crucial challenges for patients and their families.

The possibilities are certainly immense, but they require sustained R&D efforts and an environment that facilitates such developments.

According to the INE report, if we exclusively analyze the figure for companies, we observe that R&D investment increased by 5% compared to 2021. In 2022, the figure stood at 1.223 billion euros

BLUEREMEDIOMICS is expected to facilitate increased aquaculture production under more efficient food production and reduced environmental footprint scenarios.

The increasing complexity of clinical trials and evolving regulatory requirements pose significant challenges for Sponsors, CROs and Research Entities.